Published research from Veloxity Labs demonstrates a sensitive, fully validated HPLC-MS/MS method for measuring semaglutide in human plasma.

As GLP-1 receptor agonists continue to play an expanding role in therapeutic development, reliable bioanalytical methods are essential for supporting pharmacokinetic studies and clinical research.

In the second installment of our Scientific Insights Series, we highlight new peer-reviewed research published in Bioanalysis by Christopher Tudan and colleagues. The study describes the development and full validation of a sensitive HPLC-MS/MS method for semaglutide quantitation in human plasma, demonstrating how efficient sample preparation and rigorous validation can support reliable peptide bioanalysis.

Addressing the challenges of GLP-1 bioanalysis

Peptide therapeutics present distinct analytical challenges, including low circulating concentrations, complex molecular structures, potential matrix interference and nonspecific binding during sample preparation.

For GLP-1 receptor agonists such as semaglutide, developing selective and reproducible quantitative methods is particularly important for characterizing drug exposure and supporting pharmacokinetic evaluation.

The Veloxity research team developed a triple quadrupole HPLC-MS/MS method using a stable isotope-labeled internal standard and a straightforward protein precipitation extraction procedure. The approach was designed to provide sensitive, reliable quantitation while meeting established regulatory expectations for bioanalytical method validation.

Key findings from the research

The fully validated method demonstrated:

• Sensitive quantitation: A validated calibration range of 5–200 ng/mL, extendable to 1,000 ng/mL through validated dilution.
• Strong accuracy: Results ranging from 92.7% to 109.4%.
• High precision: Precision below 10.6%.
• Efficient sample preparation: A protein precipitation-based extraction approach with high analyte recovery and minimal matrix effects.
• Regulatory alignment: Full validation in accordance with the 2022 FDA M10 guidance for bioanalytical method validation.

Together, these findings establish a robust analytical approach suitable for supporting clinical studies of semaglutide within the validated concentration range and stability conditions.

Implications for peptide therapeutic development

As peptide-based therapies advance, fit-for-purpose bioanalytical methods remain critical to generating reliable pharmacokinetic data.

This research demonstrates that a relatively straightforward triple quadrupole LC-MS/MS workflow can deliver the sensitivity, accuracy, precision and selectivity required for semaglutide quantitation in human plasma.

The findings also provide a methodological foundation that may inform bioanalytical approaches for other GLP-1 peptide-based therapeutics with similar structural and physicochemical properties, subject to appropriate method development and validation.

Access the published research

Development and validation of a sensitive HPLC-MS/MS method for the analysis of semaglutide in human plasma

Christopher Tudan, Joel Stickling, Emily Northwick Darden, Lauren Devine and Shane Needham

Bioanalysis, published online August 3, 2026.

About the Scientific Insights Series

Veloxity Labs’ Scientific Insights Series highlights research, technical expertise and scientific perspectives addressing important challenges in bioanalytical science. Through peer-reviewed publications and practical insights, the series explores approaches that support reliable data generation and informed decisions throughout drug development.

Have questions about GLP-1 or peptide bioanalysis?

Connect with Veloxity Labs to discuss your program’s bioanalytical requirements.